EYEN Eyenovia Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: EYEN

Price (delayed)

$1.01

Market cap

$47.86M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.66

Enterprise value

$49.09M

Eyenovia, Inc. is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for ...

Highlights
The EPS has grown by 20% YoY
Eyenovia's net income has decreased by 7% QoQ but it has increased by 2.7% YoY
The company's quick ratio has shrunk by 71% YoY and by 51% QoQ
Eyenovia's debt has soared by 59% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://eyenoviabio.com
Peers: OPTN OPK ORGO

Key stats

What are the main financial stats of EYEN
Market
Shares outstanding
47.39M
Market cap
$47.86M
Enterprise value
$49.09M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.95
Price to sales (P/S)
10,943.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12,963.22
Earnings
Revenue
$3,787
EBIT
-$24.89M
EBITDA
-$24.11M
Free cash flow
-$27.81M
Per share
EPS
-$0.66
Free cash flow per share
-$0.68
Book value per share
$0.2
Revenue per share
$0
TBVPS
$0.65
Balance sheet
Total assets
$28.78M
Total liabilities
$19.78M
Debt
$16.08M
Equity
$9M
Working capital
$11.18M
Liquidity
Debt to equity
1.79
Current ratio
2.17
Quick ratio
1.57
Net debt/EBITDA
-0.05
Margins
EBITDA margin
-636,547.1%
Gross margin
200%
Net margin
-719,859.9%
Operating margin
-670,685.8%
Efficiency
Return on assets
-89.2%
Return on equity
-213.3%
Return on invested capital
-123.3%
Return on capital employed
-129.3%
Return on sales
-657,228.5%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EYEN stock price

How has the Eyenovia stock price performed over time
Intraday
7.45%
1 week
60.32%
1 month
12.17%
1 year
-82.43%
YTD
-51.44%
QTD
2.43%

Financial performance

How have Eyenovia's revenue and profit performed over time
Revenue
$3,787
Gross profit
$7,574
Operating income
-$25.4M
Net income
-$27.26M
Gross margin
200%
Net margin
-719,859.9%
The operating margin has soared by 66% QoQ
Eyenovia's net margin has soared by 66% from the previous quarter
EYEN's operating income is down by 9% from the previous quarter but it is up by 6% YoY
Eyenovia's net income has decreased by 7% QoQ but it has increased by 2.7% YoY

Growth

What is Eyenovia's growth rate over time

Valuation

What is Eyenovia stock price valuation
P/E
N/A
P/B
4.95
P/S
10,943.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12,963.22
The EPS has grown by 20% YoY
The company's equity fell by 48% YoY and by 43% QoQ
EYEN's P/B is 37% below its last 4 quarters average of 7.8 and 36% below its 5-year quarterly average of 7.7

Efficiency

How efficient is Eyenovia business performance
Eyenovia's ROIC has soared by 76% YoY but it has decreased by 2.8% from the previous quarter
The ROE has shrunk by 73% YoY and by 25% QoQ
The ROS has soared by 65% from the previous quarter
Eyenovia's ROA has decreased by 10% YoY and by 9% from the previous quarter

Dividends

What is EYEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EYEN.

Financial health

How did Eyenovia financials performed over time
The total assets is 45% greater than the total liabilities
The company's quick ratio has shrunk by 71% YoY and by 51% QoQ
Eyenovia's current ratio has plunged by 65% YoY and by 46% from the previous quarter
Eyenovia's debt is 79% more than its equity
Eyenovia's debt to equity has surged by 77% QoQ
Eyenovia's debt has soared by 59% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.